Emerald Holding Appoints Luke Gill to Enhance Oncology Expertise in Clinical Trials

Emerald Clinical Trials Strengthens Oncology Expertise with New Leadership Appointment

Emerald Clinical Trials, a leading global clinical research organization (CRO) headquartered in Singapore, makes a significant move to enhance its oncology capabilities by appointing Luke Gill, MSc, MBA, as the Vice President and Global Head of Oncology, Medical & Scientific Affairs. This strategic hiring underscores Emerald's commitment to advancing innovative clinical programs in oncology on a worldwide scale. With over 25 years of experience in oncology drug development, Gill brings a wealth of knowledge in overseeing a wide range of global oncology programs, from initial human trials to crucial Phase III studies and regulatory submissions.

Gill's track record includes senior roles at notable CROs, where he has successfully managed extensive oncology portfolios and cultivated partnerships with major pharmaceutical and biotech firms across the U.S., Europe, and the Asia-Pacific region. His educational background in Neuro and Molecular Pharmacology, combined with an MBA, positions him uniquely to integrate scientific knowledge with operational excellence, a vital aspect of Emerald's growth strategy. According to Glenn Kerkhof, CEO of Emerald Clinical Trials, Gill's appointment is essential for expanding the company’s oncology offerings and strengthening collaborations with biotech and pharmaceutical clients, enabling Emerald to remain competitive in a rapidly evolving industry.

In his new role, Gill will lead the expansion of Emerald's oncology portfolio and work closely with various teams to ensure the effective execution of clinical programs. His enthusiasm for joining Emerald at this pivotal moment reflects the company's shared commitment to advancing innovative oncology therapies with agility and precision. The focus on collaboration and integration of expertise aims to drive significant progress for patients and stakeholders, reinforcing Emerald's position as a key player in the global clinical trials landscape.

Emerald Clinical Trials currently serves over 100 biotech companies and six of the top ten pharmaceutical firms, providing comprehensive clinical trial services across all phases globally. As the company continues to grow its oncology capabilities, it remains dedicated to delivering high-quality, efficient services that meet the evolving needs of its clients.

For more information about Emerald Clinical Trials and its services, visit www.emeraldclinical.com.